The only player visible for the last few days was Lizzie Borden. Today vol increased but SP barely held it's own. The trading supports gaming the SP as you have explained but there are few buyers in this increased vol.
Roche agreed on Sunday to buy InterMune, sells a drug to treat a deadly lung disease, for $8.3 billion. Their only drug pirfenidone treats idiopathic pulmonary fibrosis, a fatal scarring of the lungs.
This could be GERN down the road. IMETELSTAT has shown to reverse scaring of bone marrow.
Changing the approach to treating cancer
Developing novel, first-in-class therapeutics
Working with passion fruit, integrity & true innovation
Targeting major unmet medical need
...all seems on target cept for the passion fruit...Chippy prefers Californian nuts
Second guessing the Wilmington Court's decision in applying the law in this case has been a popular board pastime for the past 8 years. Most always guessing the outcome wrong. Been out for the last few years but morbidly curious as to how such a litigation fiasco could have ever taken place. 2 more years will make it a decade.
True a remission isn't a cure but to a cance patient it means a longer extended life. JAK2 inhibitors have yet to show any remissions and at best show very limited efficacy yet ruxolitinib was fast tracked and it's use in many other indications PV under review has expanded with weak supportive efficacy data..
"This might suggest they know something about the sweat spot of the imetelstat mechanism of action." E2W, I always felt the sweat spot was owing the stock?
Why buy INCY...they have no cure, no remission or clinical improvements? For comfort you'd be better off buying a lazy boy.
INCY does own this space and perhaps part of the FDA review panel ensuring it's monopoly of the $300mil/annum MF market.
What are the next Catalyst in these stocks set to send SP higher?
GERN; Geron’s Imetelstat provides biotech investors a unique opportunity to invest in a drug in which disease modifying activity is already established and there is no competition in sight.
1. The lift on the Mayo Clinic myelofibrosis partial clinical hold practically guarantees the hold will be lifted off Geron sponsored myelofibrosis Phase II trial initiation.
2. initiation of Geron myelofibrosis trial
3. expanded disease indications ( blast & AML)
ASTY; Promising pipeline in stem cell products.
1. AST-OPC1 – Glial
Cells Current development focus:
Spinal Cord Injury 12,000 new cases per year in U.S. Phase I Trial completed in U.S. 5 Patients treated – no serious adverse events related to the OPC1 drug product to date.
Additional potential markets:
Multiple Sclerosis (“MS”) 180,000 new cases per year in U.S. Proof of principle achieved in animal models.
2. Canavan's Disease(2) Rare Proof of principle achieved in animal models.
Stroke 800,000 new cases per year in U.S. Pre-clinical research.
3. AST-VAC2 –
Dendritic Cells Current development focus:
Non-small Cell Lung Cancer 166,000 new cases per year in U.S. Cells derived and characterization studies performed (parameters analyzed showed normal cell functions in vitro(3)).
Proof of concept established in multiple human in vitro(3) systems. Scalable manufacturing methods under development.
INCY; (FDA) has accepted New Drug Application (sNDA) for ruxolitinib as a potential treatment of patients with polycythemia vera (PV) based on lack luster results from the RESPONSE Phase III trial. Although ruxolitinib has cornered the market wrt MF; offering some symptomatic relief, it has many serious side effects resulting in many patients discontinuing. The FDA keeps approving it's expanding indication applications based on weak "Comfort" trials rather than emphasizing efficacy wrt obtaining CR's and PR's.
GERN; $2.32 flat below SMA 200, 50 & 20 following strong downward trend line from Dec 2013.($2.00 by Sept.1 ) Shorts 15% Target Price $4.13 insider trading several smaller sells in April/May one large purchase by BoD member in May. 1/6th average vol.
ASTY; $2.40 down $.03 average vol.
INCY WINCY SPIDER.
INCY; $50.65 up $.46 below SMA 200, 50 in gradual upward channel. Shorts 6.5% Target price $70.77 insider trading consists of options being exercised as sales. no purchases. 7/11ths average vol
The last partial hold release on the MF MAYO trial in June was preceded with a spike in vol, and increase in SP due to seepage. Neither are present this time yet.
I agree E2W the bol bands are tightening around my neck meaning it's getting harder to breath. A big move in either direction; either I'll drop dead from asphyxiation or break loose from this noose and breath a lung full of fresh air.
gibberish or not the previous two short calls by Bulls was accurate. Their last 3 buy signals were not.
Jack I'd be the first to state that Geron has sufficient data from other clinical trials that could easily satisfy the FDA 's safety requirement. However the one patient's death in the ET & PV trials that triggered this full FDA clinical hold was suspiciously timed after the first in class efficacy CR data from the MAYO's MF study was made available. The ET/PV trials patient who died from complications due to liver failure was determined to be caused by a pre existing liver condition, hepatitus and not Imet.
INCY's resulting extended non competitive time line is what I have issue with as with GERN's current SP.
I got it with your Motesenib water skeeter analogy.....the Jesus bug is but an illusion compared its sodium based miracle making cousin Imetelstat sodium.
Appreciate the clarification Box.
Thanx from the bottom of my pond.
Maybe the answer is not sealed in the Mayo but rather in the Skippy jar.